NEWS
Catch up with the latest happenings at Treadwell Therapeutics.
Treadwell Therapeutics Announces the Appointment of J.D. Mowery, as Chief Operating Officer
April 19, 2022
Treadwell Therapeutics engages Genezen to advance its T cell receptor-based cell therapy pipeline
January 18, 2022
Treadwell Therapeutics Announces US FDA Clearance of IND Application for Phase 2 Study of TTK inhibitor, CFI-402257
November 30, 2021
Treadwell Therapeutics Announces Acquisition of TCRyption Inc., a Novel TCR-Based T Cell Therapy Company and TIO Bioventures Portfolio Company
October 15, 2021
Treadwell Therapeutics Announces the Appointment of J.D. Mowery, as Chief Operating Officer
April 19, 2022
Treadwell Therapeutics engages Genezen to advance its T cell receptor-based cell therapy pipeline
January 18, 2022
Treadwell Therapeutics Announces US FDA Clearance of IND Application for Phase 2 Study of TTK inhibitor, CFI-402257
November 30, 2021
Treadwell Therapeutics Announces Acquisition of TCRyption Inc., a Novel TCR-Based T Cell Therapy Company and TIO Bioventures Portfolio Company
October 15, 2021
Initiation of Patient Dosing in TWT-202, a Phase 1b/2 study of PLK4 Inhibitor, CFI-400945, in Patients with Leukemia
April 30, 2021
Treadwell Expands Operations with New Local Footprint at Toronto’s University Health Network
February 10, 2021
Treadwell Announces Two Presentations at the 2020 ASH Annual Meeting Featuring Clinical Trial Updates on Lead Product Candidate, CFI-400945
December 7, 2020
Treadwell Announces Initiation of New Clinical Trial of CFI-400945 in Patients with Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
October 19, 2020